LONDON, April 19, 2017 /PRNewswire/ -- In 2022, the dermatology market will be valued at $33.7 billion globally according to a report by GBI Research.
The report highlights that
● There is a lack of specialists despite the wide spread of the condition
● As a consequence, patients have access to experimental drugs
A lack of specialist
The report highlights that the most common types of disorders in the world are dermatological conditions. In the United States alone, one-third of the population suffers from at least one dermatological condition.
In the UK, the lack of qualified dermatology specialists is causing many patients to delay treatment. There are at least 200 open dermatological positions in the country.
Patients Granted Early Drug Access:
Meanwhile, British dermatology patients have been granted early access to an atopic dermatitis drug which is a severe form of eczema. The drug, dupilumab, is manufactured by Sanofi and is still experimental.
Market size and year-on-year growth is determined by a variety of factors including the increasing prevalence of acute skin conditions, chronic skin conditions, skin infections and other dermatologic diseases as well as product innovation and the increasing preference for technologically advanced services.
There are currently 801 dermatology products in the research pipeline and the conditions with the highest prevalence are acne vulgaris, atopic dermatitis, and psoriasis.
To see the report summary on ReportBuyer's blog click here.
T: +1 347 903 1913
About ReportBuyer Today:
ReportBuyer Today highlights the main
findings of top quality reports written by leading publishers.These reports
focus on several industries including Agribusiness, Life Science, Consumer
Goods & Services, IT & Media and Heavy Industries.
For more information, please visit https://www.reportbuyer.com/today/
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-dermatology-market-will-reach-34-billion-in-2022-300442142.html